Radient Pharmaceuticals poised to rise again Print E-mail
By M.E.Garza   
Sunday, 17 October 2010 19:56

As we alerted subscribers early on Friday morning,  we've been actively chasing a story about a company which TheStreet.Com called one of the top biotech stock performers of the yearRadient Pharmaceuticals Corporation (Amex: RPC).

Last April, our exclusive coverage report took Radient's shares from approximately thirty cents to over $2.50. Prior to that, the monoclonal antibody test that RPC began working on over twenty years ago- and which the FDA along with other international regulators have approved- had gone relatively unnoticed.

Two days ago, Radient and Provista Life Sciences announced the key validation study results of a new blood test for early detection of lung cancer and their press release detailed Provista's plans to broadly introduce this test to market. This was significant news. The test not only successfully detects lung cancer with a high degree of accuracy but it detects it early.

Consider that many investors who were holding shares of Biomoda (OTC:BMOD) were hit after the company announced that instead of releasing highly anticipated trial results for it's own CyPath® diagnostic assay early-stage lung cancer detection, it was extending the pilot clinical trial to recruit additional participants for the positive control group. Many investors perceived that the company was simply stalling or filibustering the release of unfavorable results and shares dropped significantly. In all fairness to Biomoda, we have reached out to the company for clarification of that news event.

Those of you who know the Radient Pharmaceuticals story know that early detection cancer is what makes the company so intriguing. While many standard drug tests can detect cancer once tumors have advanced past a certain stage/size, RPC's Onko-Sure™ in vitro diagnostic test enables physicians and their patients to effectively monitor and/or detect solid tumor cancers very early simply by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products.

The company's simple, non-invasive blood test which can detect as many as 14 different types of cancers, is said to have attracted the attention of foreign governments whose countries are not widely equipped with the the types of cancer detection imaging devices and technologies found in more further developed countries. Since patients whose cancers are detected earlier have better the odds of treatment and survival, officials in some of these countries are said to be prepared to purchase large quantities of RPC's tests for its own citizens. That could mean millions in new revenue to the company- on an on-going basis- in the very short term.

In addition, RPC and its partner, Provista Life Sciences plan to introduce their new lung cancer detection assay to market as a CLIA Laboratory Developed Test for use in highrisklung cancer patient populations in the U.S. by the end of this year through physicians, medical clinics and hospitals. Again, more positive cash-flow and profits will increase the company's already undervalued market cap.

Shorts (mostly naked) have a very big interest in the stock and positive news items like these could help lift the stock as those shorts will have to start covering their positions. That should, of course, cause additional momentum to the stock price as more buyers (longs) come in.

In short, a nice jump in RPC stock price could be in play here, especially as others begin to report and methodically examine this and rumored positive news in the days ahead.  We will follow up this report with more commentary and analysis of our own in the coming days. In the meantime, here are a couple of research links:

Our original article about the company can be found here:

The company's recent announcement about the test's lung cancer application can be found here:

Gene Marcial on Radient Phamaceuticals:

After Friday's trade alert, RPC stock rose as high at $.71 before ending the day at 0.660 +0.052 (+8.46%).  If the stock breaks past slight resistance at $.69 it would find barriers at $.86 and $.91 next.


Disclosure: No Positions

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus